Publications by authors named "Mikaela K Ribi"
Article Synopsis
- Bispecific T cell engagers (BiTEs) are designed to kill cancer cells by linking them to cytotoxic T cells, while checkpoint inhibitory T cell engagers (CiTEs) enhance this effect by reversing cancer's natural defenses against the immune system.
- Recent advancements have introduced improved chemical techniques for creating these bispecific antibodies, such as using click chemistry to assemble homogeneous, fragment-based structures.
- The study demonstrates a chemical method to produce biotin-functionalized conjugates with two CiTEs, showing that the one containing sialidase significantly boosts T cell activity against cancer cells compared to standard BiTEs.
